Photrexa cross-linking kit 6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSHC3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,337
Award facts
- Contract value 100% obligated
- $15,337.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $15,337.25 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Photorexa Cross-Linking Kit 6ml. The delivery order, issued on January 15, 2026, with an ultimate completion date of February 6, 2026, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group has served as a critical supplier within the federal pharmaceutical supply chain since its registration in the System for Award Management in 2001, demonstrating consistent performance across multiple therapeutic categories and product lines. The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036, positions the company as a regional prime vendor capable of delivering comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables to military healthcare facilities globally. No subcontractors have been identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FSHC3?
SPE2DR26FSHC3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FSHC3 worth?
The government has obligated $15,337 on SPE2DR26FSHC3.
Is contract SPE2DR26FSHC3 an order under another contract?
Yes. SPE2DR26FSHC3 is a delivery order under SPE2DR25D9305, an indefinite delivery contract.
Was contract SPE2DR26FSHC3 competed?
The extent of competition for SPE2DR26FSHC3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award